Clinical Cancer Research, Vol 4, Issue 9 2039-2045, Copyright © 1998 by American Association for Cancer Research

ARTICLES

Clinical impact of pharmacokinetically-guided dose adaptation of 5-fluorouracil: results from a multicentric randomized trial in patients with locally advanced head and neck carcinomas

R Fety, F Rolland, M Barberi-Heyob, A Hardouin, L Campion, T Conroy, JL Merlin, A Riviere, G Perrocheau, MC Etienne and G Milano
Centre Rene Gauducheau, Nantes, France. r-fety@gauducheau-nantes.fnclcc.fr

A significant link between 5-fluorouracil (5FU) plasma concentration and its therapeutic activity has been demonstrated in colon and head and neck cancer patients for 5FU used as a continuous infusion. Dose adjustment based on pharmacokinetic follow-up has been proposed to decrease hematological and digestive toxicities, but the clinical impact of this approach has not yet been demonstrated. A randomized multicentric study was conducted to evaluate the clinical interest of 5FU dose adaptation guided by pharmacokinetics. One hundred twenty-two head and neck cancer patients were randomly assigned to receive induction chemotherapy with cisplatin (100 mg/m2, day 1) and 5FU (96-h continuous infusion), either at standard dose (St-arm; 4 g/m2) or at a dose adjusted according to the 5FU area under the curve (AUC0-48h; PK-arm). In total, 106 patients were evaluable for toxicity and response. In the PK-arm (n = 49), 5FU doses and area under the curve were significantly reduced during cycle 2 and cycle 3 (P < 0.001) as compared with the St-arm (n = 57). Grade 3-4 neutropenia and thrombopenia were significantly more frequent in the St-arm as compared with the PK-arm (17.5% versus 7.6%, respectively; P = 0.013). No grade 3-4 mucositis occurred in the PK-arm, whereas 5.1% was observed in the St-arm (P < 0.01). The objective response rate was comparable in the two treatment arms: 77.2% in the St-arm versus 81.7% in the PK-arm. The present study is the first to demonstrate, in a randomized design, the clinical interest of an individual 5FU dose adaptation based on pharmacokinetic survey, in terms of therapeutic index improvement.

This article has been cited by other articles:

				A. Di Paolo, M. Lencioni, F. Amatori, S. Di Donato, G. Bocci, C. Orlandini, M. Lastella, F. Federici, M. Iannopollo, A. Falcone, et al. 5-Fluorouracil Pharmacokinetics Predicts Disease-free Survival in Patients Administered Adjuvant Chemotherapy for Colorectal Cancer Clin. Cancer Res., May 1, 2008; 14(9): 2749 - 2755. [Abstract] [Full Text] [PDF]

				L. Alnaim Therapeutic drug monitoring of cancer chemotherapy Journal of Oncology Pharmacy Practice, December 1, 2007; 13(4): 207 - 221. [Abstract] [PDF]